You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

BEXSERO: Epidemiology findings from two vaccination campaigns

Canadian-specific use of BEXSERO 1

The hyper-endemic serogroup B strain ST-269 emerged in the province of Quebec in 2003 and attributed to a steadily increasing incidence of serogroup B IMD with the Saguenay-Lac-Saint-Jean (SLSJ) region having the greatest incidence rates in Quebec.

A short-term mass immunization campaign was initiated in May 2014 with BEXSERO, targeting individuals between 2 months to 20 years of age residing or attending school in SLSJ.

The disease incidence in SLSJ from 2014 to 2018 decreased in the targeted age group.

NEW

Use of BEXSERO in the United Kingdom 1

In the UK, a national immunization program with BEXSERO was initiated in September 2015 using a two-dose schedule in infants (at 2 and 4 months of age) followed by a booster (at 12 months of age). Public Health England conducted a 3-year observational study at the national level covering the entire birth cohort from September 2015 to August 2018.

See the full study, published in 2020 in the New England Journal of Medicine

Reference:

  1. BEXSERO Product Monograph. June 12, 2020.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.